HDAC2 regulates chromatin plasticity and enhances DNA vulnerability

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 794-801

  Marchion, Douglas C ^a   Bicaku, Elona ^a   Turner, Joel G ^a   Schmitt, Morgen L ^a   Morelli, Dawn R ^a   Munster, Pamela N ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; DNA; EPIRUBICIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 6; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; SMALL INTERFERING RNA; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC ANTIBIOTIC; ENZYME INHIBITOR; HDAC1 PROTEIN, HUMAN; HDAC6 PROTEIN, HUMAN; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE-2; REPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CHROMATIN; CHROMATIN CONDENSATION; CONTROLLED STUDY; HETEROCHROMATIN; HUMAN; HUMAN CELL; HUMAN TISSUE; MORPHOLOGY; PLASTICITY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; ACETYLATION; BREAST TUMOR; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ACETYLATION; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CHROMATIN; DNA; DNA, NEOPLASM; ENZYME INHIBITORS; EPIRUBICIN; GENE EXPRESSION PROFILING; HISTONE DEACETYLASES; HISTONES; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 66449100610     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0985     Document Type: Article

References (48)

1. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A 1964;51:786-794
2. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-352 (Pubitemid 27415209)
3. Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92:1300-1304 (Pubitemid 34036893)
4. Krusche CA, Wulfing P, Kersting C, et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005;90:15-23. (Pubitemid 40486997)
5. Toh Y, Yamamoto M, Endo K, et al. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep 2003;10:333-338
6. Varshochi R, Halim F, Sunters A, et al. ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor α from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J Biol Chem 2005;280:3185-3196 (Pubitemid 40223780)
7. Saji S, Kawakami M, Hayashi S, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005;24:4531-4539 (Pubitemid 41032616)
8. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004;112:26-32. (Pubitemid 39249488)
9. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5:455-463 (Pubitemid 38610247)
10. Huang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395-404. (Pubitemid 40520691)
11. Hrzenjak A, Moinfar F, Kremser ML, et al. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 2006;5:2203-2210 (Pubitemid 44530456)
12. Bevins RL, Zimmer SG. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res 2005;65:6957-6966 (Pubitemid 41060736)
13. Jang ER, Lim SJ, Lee ES, et al. The histone deacetylase inhibitor trichostatin Asensitizes estrogen receptor α-negative breast cancer cells to tamoxifen. Oncogene 2004;23:1724-1736 (Pubitemid 38445164)
14. Johnson CA, Padget K, Austin CA, Turner BM. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J Biol Chem 2001;276:4539-4542 (Pubitemid 37371332)
15. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-7300 (Pubitemid 37413470)
16. Kurz EU, Wilson SE, Leader KB, et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase IIα expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 2001;1:121-131
17. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004;92:223-237
18. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D, Seto E. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 2000;26:349-353
19. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res 2001;61:7025-7029 (Pubitemid 32946489)
20. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001;61:1327-1333 (Pubitemid 34292551)
21. Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002;21:427-436 (Pubitemid 34123805)
22. Driever PH, Knupfer MM, Cinatl J, Wolff JE. Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr 1999;211:323-328 (Pubitemid 29364777)
23. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-6978 (Pubitemid 34062289)
24. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004;64:1079-1086 (Pubitemid 38176913)
25. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 2005;4:1993-2000.
26. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005;65:3815-3822 (Pubitemid 40616361)
27. Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIβ. Clin Cancer Res 2005;11:8467-8475 (Pubitemid 41746962)
28. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492-8497 (Pubitemid 33131130)
29. Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25:1979-1985 (Pubitemid 46972780)
30. Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581-589
31. Kramer OH, Zhu P, Ostendorff HP, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003;22:3411-3420 (Pubitemid 36834871)
32. Jones CB, McIntosh J, Huang H, Graytock A, Hoyt DG. Regulation of bleomycin-induced DNA breakage and chromatin structure in lung endothelial cells by integrins and poly(ADP-ribose) polymerase. Mol Pharmacol 2001;59:69-75. (Pubitemid 32043087)
33. Weibel ER. Quantitation in morphology: possibilities and limits. Beitr Pathol 1975;155:1-17.
34. Hyde DM, King TE, Jr, McDermott T, et al. Idiopathic pulmonary fibrosis. Quantitative assessment of lung pathology. Comparison of a semi-quantitative and a morphometric histopathologic scoring system. Am Rev Respir Dis 1992;146:1042-1047
35. Kim HS, Choi ES, Shin JA, Jang YK, Park SD. Regulation of Swi6/HP1-dependent heterochromatin assembly by cooperation of components of the mitogen-activated protein kinase pathway and a histone deacetylase Clr6. J Biol Chem 2004;279:42850-42859 (Pubitemid 39372174)
36. Zhang Y, Li N, Caron C, et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 2003;22:1168-1179 (Pubitemid 36313600)
37. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004;91:137-168 (Pubitemid 39140958)
38. Zimmermann S, Kiefer F, Prudenziati M, et al. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res 2007;67:9047-9054 (Pubitemid 47535889)
39. Lagger G, O'Carroll D, Rembold M, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002;21:2672-2681 (Pubitemid 34619383)
40. Vega RB, Matsuda K, Oh J, et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004;119:555-566 (Pubitemid 39482354)
41. Hug BA. HDAC4: a corepressor controlling bone development. Cell 2004;119:448-449 (Pubitemid 39482343)
42. McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 2000;408:106-111
43. Miska EA, Langley E, Wolf D, Karlsson C, Pines J, Kouzarides T. Differential localization of HDAC4 orchestrates muscle differentiation. Nucleic Acids Res 2001;29:3439-3447 (Pubitemid 32799117)
44. Waltregny D, Glenisson W, Tran SL, et al. Histone deacetylase HDAC8 associates with smooth muscle α-actin and is essential for smooth muscle cell contractility. FASEB J 2005;19:966-968 (Pubitemid 40827719)
45. Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-458 (Pubitemid 34563539)
46. Pandey UB, Nie Z, Batlevi Y, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007;447:859-863 (Pubitemid 46920134)
47. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004;24:8467-8476 (Pubitemid 39245069)
48. Daud A, Schmitt M, Marchion D, et al. Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies [abstract 3502]. J Clin Oncol 2007;25:3502.